VivoSim Labs, INC.
Close on Oct 19, 2026
- Market cap
- $825.22K
- P/E (TTM)
- –
- Dividend yield
- –
About VivoSim Labs
Biological Products, (No Diagnostic Substances), SIC 2836
VivoSim Labs, Inc. is a pharmaceutical and biotechnology services company that provides drug and drug candidate testing using three-dimensional human tissue models of the liver and intestine. The company offers liver and intestinal toxicology insights and predictive screening through its new approach methodologies models, which are designed to forecast adverse effects and intestinal tolerability across various phases of drug development. Its primary customers include pharmaceutical and biotechnology companies seeking to evaluate therapeutic candidates and elucidate drug mechanisms of action.
The company conducts its operations from principal executive offices in San Diego, California. VivoSim Labs operates alongside its subsidiaries and maintains intellectual property rights spanning multiple international jurisdictions, including Australia, Canada, China, Japan, and several European nations. As of June 2026, the organization employed 15 individuals, including 9 full-time workers, supplemented by scientific and operational consultants.
Summary of the business section of VivoSim Labs's latest annual report, written by StockData.
Company profile
Company
- Legal name
- VivoSim Labs, INC.
- Founded
- 2007
- Headquarters
- San Diego, CA
- Address
- 11555 Sorrento Valley Road, Suite 100 92121
- Phone
- (858) 224-1000
- Website
- vivosim.ai
- Employees
- 15, Mar 31, 2026
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- March 31
- Auditor
- Rosenberg Rich Baker Berman, P.A., Somerset, New Jersey
Stock & identifiers
- Ticker
- VIVS
- Exchange
- Nasdaq
- IPO date
- Feb 14, 2012
- Shares outstanding
- 15M, Aug 10, 2026
- Public float
- $7.54M, Sep 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-12 reverse, Mar 31, 2025; 1-for-12 reverse, Mar 21, 2025; 1-for-20 reverse, Aug 19, 2020; 1-for-20 reverse, Aug 18, 2020
- SEC CIK
- 1497253
- CUSIP
- 68620A302
- ISIN
- US68620A3023
- EIN
- 27-1488943
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Keith Murphy | EXECUTIVE CHAIRMAN, Director | 6,094,968 |
| Tony Serge Lialin | Chief Commercial Officer | 10,000 |
| Amar Akhtar Sethi | Chief Scientific Officer | – |
| Norm Staskey | See Remarks | – |
| David Gobel | Director | 15,000 |
| Douglas Jay Cohen | Director | 20,898 |
| Adam K. Stern | Director | 522,988 |
| Alison Tjosvold Milhous | Director | 19,899 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2026 Mr. Murphy | $865.96K | $779.74K | $217.59K | $1 | – |
| FY2025 Mr. Murphy | $1.17M | $887.67K | $135.90K | $2 | – |
| FY2024 Mr. Murphy | $681.14K | $595.61K | $343.08K | $11 | – |
| FY2023 Mr. Murphy | $621.45K | $368.25K | $390.86K | $23 | – |
| FY2022 Mr. Murphy | $1.26M | -$24.88K | $779.56K | $39 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of June 1, 2026, we had 15 employees, of which 9 are full-time.”
Corporate history
Events identified from SEC filings